source clustersSource Clusters is the single source of information on regional development in the life sciences sector worldwide.

With content providing broad overviews as well as in-depth coverage of business development trends, company activities, life science cluster collaborations, multi-partner scientific projects and its extensive news coverage, Source Clusters presents the latest management, research, technology and regional development information serving the needs of executives in the internationally growing life sciences sector.

Source Clusters is the essential resource for companies, incubators, science parks, clusters and regional development agencies looking to find a new location or attract new business and exploit new opportunities across the life sciences sector.

TxCell terminates OCABSA financing programme following majority stake acquisition by Sangamo

TxCell logo 10.7.18Sangamo Therapeutics logo 7.11.18French company TxCell SA, a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, recently announced that the actions provided for by the agreement it entered into with Yorkville in July 2018 to further improve the terms of its OCABSA financing programme in line with the closing of California-based Sangamo Therapeutics’ acquisition of a majority stake in the company have now been completed as planned and the OCABSA programme has therefore been terminated.

The programme consisted of monthly instalments for a maximum nominal amount of €1.2 million each at TxCell’s sole discretion for a total potential fundraising of up to €20 million through the exercise by Yorkville, upon the request of TxCell, of warrants giving access to notes with share subscription warrants attached.

For further information about TxCell visit www.txcell.com and for further information about Sangamo visit www.sangamo.com

Last modified onWednesday, 07 November 2018 09:59